A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to keep making copies of Eli ...

A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...

A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...

Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs, ...

As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper ...

Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range ...

Eli Lilly is now offering four doses of Zepbound in self-administration vials. The lower-cost self-pay option targets people ...

Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

The move positions Lilly as a competitive alternative to compounded weight-loss drugs, especially as the FDA cracks down on off-brand versions. Eli Lilly announced in a press release last week ...